~~<i id='6B8DD58D2D'><strike id='6B8DD58D2D'><tt id='6B8DD58D2D'><pre id='6B8DD58D2D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：explore 2025-09-29 00:27:16 - browse：22

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Naloxone nonprofit donates 200,000 doses after FDA approval

hotspot

leisure time

Wikipedia

focus

hotspot

0:26InthisundatedphotoprovidedbyElRoiHaiti,AlixDorsainvil,right,poseswithherhusband,SandroDorsainvil

WSS

In same hospitals, Black patients receive fewer opioids than white patients

Naloxone nonprofit donates 200,000 doses after FDA approval

South Korea throws huge K

The Karikó problem: Lessons for funding basic research

Congress extends some pandemic preparedness programs

Emergent cuts jobs, executive role in business shake

hotspot

explore

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Drastic changes should bring profitability, startup health insurers say

Bright Health sells Medicare Advantage business to Molina

Naloxone nonprofit donates 200,000 doses after FDA approval

The cancer drug shortage isn’t new — and neither are the solutions

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Bright Health sells Medicare Advantage business to Molina

IVG is promising — but it won’t replace IVF quite yet

hotspot

The best solution to the drug shortages problem

European officials brace for rough respiratory virus season

A biotech analyst on neuroscience, placebo effect, not over

In same hospitals, Black patients receive fewer opioids than white patients

6 solutions to address cancer drug shortages and others

Will an HIV vaccine ever be a reality?

leisure time

Wikipedia

focus

hotspot